The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02981290




Registration number
NCT02981290
Ethics application status
Date submitted
1/12/2016
Date registered
5/12/2016
Date last updated
5/12/2016

Titles & IDs
Public title
Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants
Scientific title
A Randomized, Open Label, Four-way Crossover Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Subjects
Secondary ID [1] 0 0
WP21980
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Renodapt
Treatment: Drugs - Mycept
Treatment: Drugs - Cellmune
Treatment: Drugs - CellCept

Experimental: Renodapt Then Mycept Then Cellmune Then CellCept - Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.

Experimental: Mycept Then CellCept Then Renodapt Then Cellmune - Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.

Experimental: Cellmune Then Renodapt Then CellCept Then Mycept - Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.

Experimental: CellCept Then Cellmune Then Mycept Then Renodapt - Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.


Treatment: Drugs: Renodapt
Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.

Treatment: Drugs: Mycept
Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Treatment: Drugs: Cellmune
Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Treatment: Drugs: CellCept
CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of MPA
Timepoint [1] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Primary outcome [2] 0 0
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of MPA
Timepoint [2] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Primary outcome [3] 0 0
Maximum Observed Plasma Concentration (Cmax) of MPA
Timepoint [3] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Primary outcome [4] 0 0
Time to Reach Maximum Observed Plasma Concentration (Tmax) of MPA
Timepoint [4] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Primary outcome [5] 0 0
Absorption Lag Time (Tlag) of MPA
Timepoint [5] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Primary outcome [6] 0 0
Plasma Terminal Half-Life (t1/2) of MPA
Timepoint [6] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Primary outcome [7] 0 0
Apparent Oral Clearance (CL/F) of MPA
Timepoint [7] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [1] 0 0
Apparent Oral Volume of Distribution (V/F) of MPA
Timepoint [1] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [2] 0 0
AUC (0-inf) of the Glucuronide Metabolite of MPA (MPAG)
Timepoint [2] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [3] 0 0
AUClast of MPAG
Timepoint [3] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [4] 0 0
Cmax of MPAG
Timepoint [4] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [5] 0 0
Tmax of MPAG
Timepoint [5] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [6] 0 0
Tlag of MPAG
Timepoint [6] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [7] 0 0
t1/2 of MPAG
Timepoint [7] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [8] 0 0
CL/F of MPAG
Timepoint [8] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [9] 0 0
V/F of MPAG
Timepoint [9] 0 0
Predose (0.5 hours), and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 hours post dose on Day 1
Secondary outcome [10] 0 0
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [10] 0 0
Baseline up to 9 weeks

Eligibility
Key inclusion criteria
A body mass index (BMI) between 18 and 32 kilogram per meter square (kg/m^2)
Minimum age
18 Years
Maximum age
55 Years
Gender
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Any evidence of clinically significant allergic, renal, cardiac, bronchopulmonary,
vascular, gastro-intestinal, neurological, metabolic or immunodeficiency disorders,
cancer, hepatitis or cirrhosis

- Any evidence of gall bladder surgery, surgery of the gastro-intestinal tract or any
other medical condition considered likely to affect drug absorption

- Any major illness within 2 months prior to first dosing or febrile illness within 14
days prior to first dosing

- Any known history of clinically significant allergic reactions or drug
hypersensitivity, especially hypersensitivity to MMF or mycophenolic acid (MPA)

- Any other ongoing concomitant disease or condition that could interfere with, or the
treatment of which might interfere with, the conduct of the study, or that would, in
the opinion of the investigator, pose an unacceptable risk to the participants

- Any prescribed or over-the-counter (OTC) medication, herbal medicine or dietary aid
taken within 2 weeks before the first study drug dosing or within six times the
elimination half-life of the medication before the first study drug dosing

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a single center, randomized, open label, 4-treatment, 4-period, 4-sequence, 4-way
crossover study to compare the pharmacokinetics of mycophenolate mofetil (MMF) metabolites
from 4 tablet formulations in healthy participants.
Trial website
https://clinicaltrials.gov/show/NCT02981290
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications